News
HRTX
0.4185
-3.42%
-0.0148
Weekly Report: what happened at HRTX last week (0615-0619)?
Weekly Report · 3d ago
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
TipRanks · 06/16 19:17
Weekly Report: what happened at HRTX last week (0608-0612)?
Weekly Report · 06/15 09:41
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)
Seeking Alpha · 06/10 13:00
Heron Therapeutics (HRTX) Receives a Buy from H.C. Wainwright
TipRanks · 06/08 10:36
Weekly Report: what happened at HRTX last week (0601-0605)?
Weekly Report · 06/08 09:38
X4, TripAdvisor, Heron, DigitalOcean, Shake Shack Trending
TipRanks · 06/06 09:01
Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday
Benzinga · 06/03 12:52
Heron Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 06/03 11:37
Heron Therapeutics Price Target Cut to $2.00/Share From $4.00 by HC Wainwright & Co.
Dow Jones · 06/03 11:37
HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2
Benzinga · 06/03 11:26
Heron Therapeutics Cut to Hold From Buy by Needham
Dow Jones · 06/03 10:26
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
TipRanks · 06/03 10:17
Needham Downgrades Heron Therapeutics to Hold
Benzinga · 06/03 10:16
HERON THERAPEUTICS, INC. <HRTX.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $2 FROM $4
Reuters · 06/03 10:07
U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty
Reuters · 06/03 07:55
HERON THERAPEUTICS INC <HRTX.O>: NEEDHAM CUTS TO HOLD FROM BUY
Reuters · 06/03 03:07
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
TipRanks · 06/02 23:09
Heron Therapeutics downgraded at Needham after Cinvanti patents invalidated
TipRanks · 06/02 20:24
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Heron Therapeutics (HRTX) and Praxis Precision Medicines (PRAX)
TipRanks · 06/02 20:10
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.